Home › Funds › NEXPOINT ASSET MANAGEMENT, L.P. › RNA
NEXPOINT ASSET MANAGEMENT, L.P. position in RNA
ATRIUM THERAPEUTICS INC · Health Care
NEXPOINT ASSET MANAGEMENT, L.P. reported holding 150,025 shares of RNA (ATRIUM THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$2.0M, representing 0.14% of its reported portfolio and ranking #45 among its reported holdings. NEXPOINT ASSET MANAGEMENT, L.P. has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How NEXPOINT ASSET MANAGEMENT, L.P.'s RNA position evolved
NEXPOINT ASSET MANAGEMENT, L.P. first disclosed a stake in RNA in Q1 2026 at 150,025 shares (US$2.0M). The position peaked in Q2 2026 at 150,025 shares, worth US$2.0M. Across 2 filings, NEXPOINT ASSET MANAGEMENT, L.P. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 150,025 shares valued at US$2.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 150.03K | $2.01M | New |
| Q2 2026 | 150.03K | $2.02M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RNA and 13F data
RNA (ATRIUM THERAPEUTICS INC) is a Health Care company. 116 other funds we track also report a position in RNA — the largest reported positions include Sessa Capital IM, L.P. (US$20.2M), CRCM LP (US$8.6M), TIG Advisors, LLC (US$7.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RNA
- Sessa Capital IM, L.P. 1.50M sh · $20.18M · Q2 2026
- CRCM LP 641.54K sh · $8.63M · Q2 2026
- TIG Advisors, LLC 561.53K sh · $7.55M · Q2 2026
- Arbiter Partners Capital Management LLC 261.29K sh · $3.51M · Q2 2026
- Slotnik Capital, LLC 237.64K sh · $3.20M · Q2 2026
- Bracebridge Capital, LLC 139.24K sh · $1.87M · Q2 2026
- Yakira Capital Management, Inc. 133.05K sh · $1.79M · Q2 2026
- Creek Drive Management Group LLC 127.60K sh · $1.72M · Q2 2026
- Athos Capital Ltd 107.97K sh · $1.45M · Q2 2026
- Marble Bar Asset Management LLP 103.85K sh · $1.40M · Q2 2026
- ALETHEA CAPITAL MANAGEMENT, LLC 43.76K sh · $588.54K · Q2 2026
- Trium Capital LLP 58.38K sh · $483.40K · Q3 2026
More on NEXPOINT ASSET MANAGEMENT, L.P.
FAQ
How long has NEXPOINT ASSET MANAGEMENT, L.P. held RNA?
NEXPOINT ASSET MANAGEMENT, L.P. has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is NEXPOINT ASSET MANAGEMENT, L.P.'s current position in RNA?
As of Q2 2026, NEXPOINT ASSET MANAGEMENT, L.P. holds 150.03K shares of RNA (ATRIUM THERAPEUTICS INC), valued at $2.02M, representing 0.14% of its reported portfolio and ranking #45.
Has NEXPOINT ASSET MANAGEMENT, L.P. been buying or selling RNA?
In the latest 13F filing (Q2 2026), NEXPOINT ASSET MANAGEMENT, L.P. held unchanged its position in RNA. The position peaked in Q2 2026 at 150.03K shares.
Which other funds hold RNA?
Other major institutional holders of RNA include Sessa Capital IM, L.P., CRCM LP, TIG Advisors, LLC, among 116 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.